Nanaimo-based Tilray has announced the launch of a new brand of medical cannabis products.
According to a press release this month, Symbios was launched “as a complement to the company’s existing medical brand portfolio in Canada,” with flower, oils and pre-rolls set at a “better price point” for patients’ health and wellness needs.
Tilray also announced a line of new high-potency medical cannabis topical products under the Aphria brand name that are formulated to target inflammatory joint disease when applied to the skin.
“Symbios and our new Aphria topical treatments are exciting new additions to our medical portfolio in Canada, providing our patients with a broader selection of unique product formats to meet their needs and preferences,” said Jim Meiers, president of Tilray Canada, in the release. “Our industry is only in the early stages of creating and bringing to market cannabinoid medicine options that meet patient needs. We are committed to building our leadership position in Canada now and into the future.”
Tilray and Aphria announced a merger of the two companies in December and now market the companies’ cannabis brands under the Tilray corporate name.
Irwin D. Simon, Tilray’s chief executive officer, said medical cannabis innovation and patient care are core to the new Tilray’s business and global growth strategy. “As we look ahead, we remain focused on building momentum across our three medical brands – Symbios, Aphria, and Tilray – while meeting the large and growing demand for new, high-quality cannabis products that promote health, wellness, and wellbeing,” he said.